Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Oct 3;5(10):e2234971.
doi: 10.1001/jamanetworkopen.2022.34971.

Survival Benefit of First Single-Organ Deceased Donor Kidney Transplantation Compared With Long-term Dialysis Across Ages in Transplant-Eligible Patients With Kidney Failure

Susanne Strohmaier  1   2 , Christine Wallisch  2 , Michael Kammer  2   3 , Angelika Geroldinger  2 , Georg Heinze  2 , Rainer Oberbauer  3 , Maria C Haller  2   4
Affiliations
Randomized Controlled Trial

Survival Benefit of First Single-Organ Deceased Donor Kidney Transplantation Compared With Long-term Dialysis Across Ages in Transplant-Eligible Patients With Kidney Failure

Susanne Strohmaier et al. JAMA Netw Open. .

Abstract

Importance: Kidney transplant is considered beneficial in terms of survival compared with continued dialysis for patients with kidney failure. However, randomized clinical trials are infeasible, and available evidence from cohort studies is at high risk of bias.

Objective: To compare restricted mean survival times (RMSTs) between patients who underwent transplant and patients continuing dialysis across transplant candidate ages and depending on waiting time, applying target trial emulation methods.

Design, setting, and participants: In this retrospective cohort study, patients aged 18 years or older appearing on the wait list for their first single-organ deceased donor kidney transplant between January 1, 2000, and December 31, 2018, in Austria were evaluated. Available data were obtained from the Austrian Dialysis and Transplant Registry and Eurotransplant and included repeated updates on wait-listing status and relevant covariates. Data were analyzed between August 1, 2019, and December 23, 2021.

Exposures: A target trial was emulated in which patients were randomized to either receive the transplant immediately (treatment group) or to continue dialysis and never receive a transplant (control group) at each time an organ became available.

Main outcomes and measures: The primary outcome was time from transplant allocation to death. Effect sizes in terms of RMSTs were obtained using a sequential Cox approach.

Results: Among the 4445 included patients (2974 men [66.9%]; mean [SD] age, 52.2 [13.2] years), transplant was associated with increased survival time across all considered ages compared with continuing dialysis and remaining on the wait list within a 10-year follow-up. The estimated RMST differences were 0.57 years (95% CI, -0.14 to 1.84 years) at age 20 years, 3.01 years (95% CI, 2.50 to 3.54 years) at age 60 years, and 2.48 years (95% CI, 1.88 to 3.04 years) at age 70 years. The survival benefit for patients who underwent transplant across ages was independent of waiting time.

Conclusions and relevance: The findings of this study suggest that kidney transplant prolongs the survival time of persons with kidney failure across all candidate ages and waiting times.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: No disclosures were reported.

Figures

Figure 1.
Figure 1.. Derivation of the Study Cohort
OEDTR indicates Austrian (Oesterreichische) Dialysis and Transplant Registry.
Figure 2.
Figure 2.. Restricted Mean Survival Times for All-Cause Mortality and Differences Thereof
A, Five-year and 10-year restricted mean survival times for all-cause mortality. B, Five-year and 10-year restricted mean survival times for all-cause mortality differences. Shaded areas indicate 95% CIs.
Figure 3.
Figure 3.. Restricted Mean Survival Times Conditional on Wait-listing Duration
A, Five-year and 10-year restricted mean survival times for all-cause mortality conditional on different times on wait list. B, Five-year and 10-year restricted mean survival times for all-cause mortality and differences conditional on different times on wait list. Shaded areas indicate 95% CIs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yang F, Liao M, Wang P, Yang Z, Liu Y. The cost-effectiveness of kidney replacement therapy modalities: a systematic review of full economic evaluations. Appl Health Econ Health Policy. 2021;19(2):163-180. doi:10.1007/s40258-020-00614-4 - DOI - PMC - PubMed
    1. Wong G, Howard K, Chapman JR, et al. . Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. PLoS One. 2012;7(1):e29591. doi:10.1371/journal.pone.0029591 - DOI - PMC - PubMed
    1. Haller M, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R. Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant. 2011;26(9):2988-2995. doi:10.1093/ndt/gfq780 - DOI - PubMed
    1. Tonelli M, Wiebe N, Knoll G, et al. . Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011;11(10):2093-2109. doi:10.1111/j.1600-6143.2011.03686.x - DOI - PubMed
    1. Jensen CE, Sørensen P, Petersen KD. In Denmark kidney transplantation is more cost-effective than dialysis. Dan Med J. 2014;61(3):A4796. - PubMed

Publication types